Importer of Controlled Substances Application: Alcami Carolinas Corporation, 36941 [2019-16164]
Download as PDF
<![CDATA[
36941
Federal Register / Vol. 84, No. 146 / Tuesday, July 30, 2019 / Notices
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers.
Dated: July 16, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–16176 Filed 7–29–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
In
accordance with 21 CFR 1301.34(a), this
is notice that on May 8, 2019, Alcami
Carolinas Corporation, 1726 North 23rd
Street, Wilmington, North Carolina
28405 applied to be registered as an
importer of the following basic classes
of controlled substances:
SUPPLEMENTARY INFORMATION:
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Alcami Carolinas
Corporation
ACTION:
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Notice of application.
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: July 16, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–16164 Filed 7–29–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
Notice of registration.
The registrant listed below
has applied for and been granted
registration by the Drug Enforcement
Administration (DEA) as an importer of
schedule I or schedule II controlled
substances.
SUMMARY:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 29, 2019. Such persons
may also file a written request for a
hearing on the application on or before
August 29, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
DATES:
Drug
code
Controlled substance
Psilocybin .................
Psilocyn ....................
Thebaine ...................
Pentobarbital ............
7437
7438
9333
2270
Schedule
I
I
II
II
The company plans to import the
listed controlled substances in bulk for
the manufacturing of capsules/tablets
for Phase II clinical trials. Approval of
permit applications will occur only
when the registrant’s activity is
consistent with what is authorized
SUPPLEMENTARY INFORMATION:
The company listed below applied to
be registered as an importer of various
basic classes of controlled substances.
Information on the previously published
notice is listed in the table below. No
comments or objections were submitted
and no requests for a hearing were
submitted for this notice.
Company
FR docket
jspears on DSK3GMQ082PROD with NOTICES
AndersonBrecon, Inc ............................................................................................................................................
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of the
listed registrant to import the applicable
basic classes of schedule I or II
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I controlled substances to the
above listed company.
VerDate Sep<11>2014
16:42 Jul 29, 2019
Jkt 247001
Dated: July 16, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019–16169 Filed 7–29–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Research Triangle
Institute
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 29, 2019. Such persons
may also file a written request for a
DATES:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
84 FR 21813
Published
May 15, 2019.
hearing on the application on or before
August 29, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR
1301.34(a), this is notice that on May 03,
2019, Research Triangle Institute, 3040
East Cornwallis Road, Hermann
E:\FR\FM\30JYN1.SGM
30JYN1
]]>Agencies
[Federal Register Volume 84, Number 146 (Tuesday, July 30, 2019)]
[Notices]
[Page 36941]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16164]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Alcami Carolinas
Corporation
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 29, 2019.
Such persons may also file a written request for a hearing on the
application on or before August 29, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 8, 2019, Alcami Carolinas Corporation, 1726 North
23rd Street, Wilmington, North Carolina 28405 applied to be registered
as an importer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Psilocybin............................ 7437 I
Psilocyn.............................. 7438 I
Thebaine.............................. 9333 II
Pentobarbital......................... 2270 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
bulk for the manufacturing of capsules/tablets for Phase II clinical
trials. Approval of permit applications will occur only when the
registrant's activity is consistent with what is authorized under 21
U.S.C. 952(a)(2). Authorization will not extend to the import of FDA
approved or non-approved finished dosage forms for commercial sale.
Dated: July 16, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-16164 Filed 7-29-19; 8:45 am]
BILLING CODE 4410-09-P
